Treatment of refractory chronic urticaria: current and future therapeutic options (Q38148494)

29 August 2017

title

Treatment of refractory chronic urticaria: current and future therapeutic options (English)

1 reference

29 August 2017

1 reference

1 reference

Massimo Cugno

3

0 references

author name string

Riccardo Asero

series ordinal

1

1 reference

29 August 2017

Alberto Tedeschi

series ordinal

2

1 reference

29 August 2017

publication date

1 December 2013

1 reference

American Journal of Clinical Dermatology

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

481-488

1 reference

https://scigraph.springernature.com/pub.10.1007/s40257-013-0047-3

29 August 2017

exact match

0 references

cites work

Chronic urticaria: recent advances

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

EAACI/GA2LEN/EDF guideline: management of urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

BSACI guidelines for the management of chronic urticaria and angio-oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Diagnosis and treatment of urticaria and angioedema: a worldwide perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Leukotriene receptor antagonists in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Zafirlukast has no beneficial effects in the treatment of chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Urticaria treated with dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Cyclosporine-A in severe chronic urticaria: the option for long-term therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Chronic urticaria: a role for newer immunomodulatory drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Effect of omalizumab on patients with chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Treatment of chronic autoimmune urticaria with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Warfarin treatment of chronic idiopathic urticaria and angio-oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Plasmapheresis for severe, unremitting, chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Experience with cyclosporine in children with chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

Expression of Tissue Factor by Eosinophils in Patients with Chronic Urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0047-3

10.1007/S40257-013-0047-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1038907161

0 references

1 reference